Basal insulin peglispro (BIL) is a novel insulin analogue that binds insulin lispro covalently via a urethane bond to a 20-kDa polyethylene glycol molecule (PEG). This analogue, therefore, has a molecular weight of~25.8 kDa, approximately three times greater than that of native insulin or most insulin analogues. Its hydrodynamic size, however, appears to be even larger,~90 kDa, similar to a globular protein such as human albumin.
and excreted from the body via both renal and hepato-biliary routes.
The pharmacokinetic profile of pegylated lispro is prolonged when administered by subcutaneous injection, with a half-life of 2-3 days, which is significantly longer than that of any of the other available insulin analogues. 1 It has been proposed that large insulin analogues must pass through the capillary wall, lined by a continuous endothelium, and the rate of diffusion is inversely related to their molecular size. 4 In contrast, within the liver there are highly fenestrated cells that line the vascular sinusoids and thus there is no barrier to prevent insulin diffusion. 4 In normal physiology, insulin is secreted by the pancreas into the hepatic portal vein that delivers insulin directly to the liver and thus the liver sees four times the concentration in comparison with other tissues supplied by the systemic peripheral circulation. 4 It has therefore been proposed that larger insulin molecules are more likely to be relatively hepato-preferential, and some have suggested this might be a strategy to achieve more physiological insulin replacement via the subcutaneous route.
Moore et al. 5 in animals and Henry et al. 6 I hope this is only the end of the beginning and that others will not be deterred in the future from developing hepato-preferential
analogues that offer such potential advantages.
